KYMR VS ABBV Stock Comparison
Performance
KYMR10/100
10/100
KYMR returned -38.95% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ABBV100/100
100/100
ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.
Sentiment
KYMR69/100
69/100
KYMR had a bullish sentiment score of 68.98% across Twitter and StockTwits over the last 12 months. It had an average of 2.55 posts, 2.33 comments, and 0.61 likes per day.
ABBV71/100
71/100
ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.
Technicals
KYMR75/100
75/100
KYMR receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.
ABBV11/100
11/100
ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
KYMR10/100
10/100
KYMR has missed earnings 11 times in the last 20 quarters.
ABBV100/100
100/100
ABBV has missed earnings 0 times in the last 20 quarters.
Profit
KYMR10/100
10/100
Out of the last 17 quarters, KYMR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
ABBV80/100
80/100
Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.
Volatility
KYMR47/100
47/100
KYMR has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
ABBV47/100
47/100
ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Analyst Price Targets
KYMR
"Analyst Price Targets" not found for KYMR
ABBV68/100
68/100
20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.
Dividend
KYMR
"Dividend" not found for KYMR
ABBV100/100
100/100
ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Kymera Therapeutics, Inc. Common Stock Summary
Nasdaq / KYMR
Healthcare
Biotechnology
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
ABBVIE INC. Summary
New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare KYMR to other companies in the same or a similar industry.